Adverse drug event reporting. Improving the low US reporting rates.

The United States has low adverse drug event (ADE) spontaneous reporting rates compared with those of other developed countries (1983). Although slightly lower reporting rates are experienced in the Netherlands, France, Germany, and Belgium, US reporting rates are on the average approximately 25% of those in Denmark, 40% of those in Canada, and 50% of those in the United Kingdom.1This is despite demonstrated successes in identifying potentially dangerous and ineffective drugs by the spontaneous reporting system (SRS), regular distribution of reporting forms to health providers by the Food and Drug Administration (FDA), and frequent periodic articles in scientific journals and presentations at national and international meetings explaining and promoting spontaneous reporting. See also p 1596. The FDA's SRS began in 1960 and was computerized in 1969. Since 1969, over 360000 reports have been computerized.2The 1984 ADE reporting rate was approximately 15 reports per million prescriptions dispensed

[1]  G. Venning.  Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. , 1983, British medical journal.

[2]  L A Tanner,et al.  Food and Drug Administration monitoring of adverse drug reactions. , 1986, American journal of hospital pharmacy.

[3]  S. G. Bryant,et al.  Detecting Adverse Drug Reactions in Postmarketing Surveillance: Interview Validity , 1987 .

[4]  G. Faich,et al.  The Processing of Adverse Reaction Reports at FDA , 1986 .

[5]  G. Venning.  Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. , 1983, British medical journal.

[6]  D. Levine,et al.  Physician knowledge, attitudes, and behavior related to reporting adverse drug events. , 1988, Archives of internal medicine.

[7]  G. Venning.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? , 1983, British medical journal.

[8]  G. Faich,et al.  Differences in Manufacturer Reporting of Adverse Drug Reactions to the FDA in 1984 , 1987 .

[9]  M. Stephens.  The diagnosis of adverse medical events associated with drug treatment. , 1987, Adverse drug reactions and acute poisoning reviews.

[10]  J. Venulet.  Informativity of Adverse Drug Reactions Data in Medical Publications , 1985 .

[11]  M. Girard.  Data quality in post-marketing surveillance. , 1986, Adverse drug reactions and acute poisoning reviews.

[12]  G. Venning.  Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? , 1983, British medical journal.

[13]  Griffin Jp,et al.  Voluntary systems of adverse reaction reporting--Part III. , 1985 .

[14]  D E Knapp,et al.  Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. , 1983, JAMA.